Acadian Asset Management LLC Acquires New Stake in Omnicell, Inc. $OMCL

Acadian Asset Management LLC acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 125,843 shares of the company’s stock, valued at approximately $4,394,000. Acadian Asset Management LLC owned 0.27% of Omnicell as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the business. Diversified Trust Co boosted its stake in Omnicell by 2.3% during the first quarter. Diversified Trust Co now owns 22,660 shares of the company’s stock valued at $792,000 after buying an additional 513 shares during the period. Bridge City Capital LLC boosted its stake in Omnicell by 1.6% during the first quarter. Bridge City Capital LLC now owns 40,136 shares of the company’s stock valued at $1,403,000 after buying an additional 650 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Omnicell by 4.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,832 shares of the company’s stock valued at $553,000 after buying an additional 696 shares during the period. EntryPoint Capital LLC boosted its stake in Omnicell by 21.6% during the first quarter. EntryPoint Capital LLC now owns 6,671 shares of the company’s stock valued at $233,000 after buying an additional 1,184 shares during the period. Finally, Empowered Funds LLC boosted its stake in Omnicell by 14.3% during the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after buying an additional 1,243 shares during the period. Institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on OMCL. Piper Sandler lowered their price target on Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Wall Street Zen downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Wells Fargo & Company raised their price target on Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, July 21st. Finally, Bank of America raised their price target on Omnicell from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, May 23rd. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Omnicell Stock Down 4.4%

OMCL opened at $31.83 on Monday. The company has a market cap of $1.46 billion, a P/E ratio of 63.66, a P/E/G ratio of 6.95 and a beta of 0.82. The business’s 50-day moving average price is $30.71 and its 200-day moving average price is $31.00. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities analysts expect that Omnicell, Inc. will post 1.09 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.